ArQule stock: buy or sell?
September 20th, 2019
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.
Should I buy ArQule stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, ArQule stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is ArQule stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 5 ratings published for ARQL stock in the last 30 days. The general sentiment of these ratings is bullish for ARQL stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-19||Royal Bank of Canada||n/a||Outperform|
|2019-5-2||Royal Bank of Canada||n/a||Buy|
|2019-4-11||Royal Bank of Canada||n/a||Outperform|
ArQule stock analysis
ArQule shares climbed 4.61% to $8.39 today.
ArQule climbed a super good 4.61% and closed at $8.39. ARQL is soaring again after a 8.29% correction from its last top on September/11 at $8.44. On May, SMA100d and SMA200d crossed up triggering a rise of 17.02%. Since price and SMA100d lines crossed down on September/9, ARQL fell $-0.93 per share (-9.98%).
After sliding a bloodcurdling -16.94% in a week last week, ArQule closed this week at $8.39 and boosted a wonderful 5.27%.
ARQL marked an uptrend of rising tops and rising bottoms. Since its last top early July at $12.22, price slid and bounced up back from $7.52. Breaking down under $7.52 would cancel the current uptrend and it might test lower supports. Note that $12.22 might act as a resistance line. By mid May, SMA20w and SMA40w crossed up triggering a rise of 30.69%. Since early March when ARQL stock price broke up the SMA40w line, it gained $4.83 (135.67%).
ArQule stock price history
ArQule stock went public on October 16th, 1996 with a price of $12.251. Since then, ARQL stock lost a -31.50%, with a yearly average of -1.40%.
1: Adjusted price after possible price splits or reverse-splits.
ArQule stock historical price chart
ARQL stock reached 52-week highs on July at $12.22, and all-time highs 2000-02-17 with a price of 40.38.
ArQule stock price target is $12.00How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ARQL stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 4 price targets for ArQule stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-19||Royal Bank of Canada||Raises Target||n/a||$12.00||-|
|2019-6-14||Roth Capital||Raises Target||n/a||$13.00||-|
|2019-5-2||Royal Bank of Canada||Set Price Target||n/a||$10.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, ArQule reported its latest financial data, close to analysts' consensus and posted a $-0.08 Earnings per Share. As soon as we get its posted EPS from the earnings report, we will update this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2016, last anual revenues report draw a dazzling gain of 447.12% to $25.76 million dollars. When comparing 2018 vs 2016, in line, profit margin (that is, the net income divided by revenues) rocketed a 422.35% to -60.09%.
|2013||$16 M||-||$-24.60 M-154.6%||-|
|2014||$11 M||-29.26%||$-23.39 M-207.8%||-4.91%|
|2015||$11 M||-0.13%||$-13.77 M-122.6%||-41.11%|
|2016||$4.71 M||-58.10%||$-22.72 M-482.4%||64.93%|
|2018||$26 M||447.12%||$-15.48 M-60.1%||-31.85%|
Quarterly financial resultsArQule reported $2.94 M in revenues for 2018-Q4, a -40.93% decline compared to previous quarter. Reported quarter earnings marked $-8.49 M with a profit margin of -288.58%. Profit margin plummed a -175.72% compared to previous quarter when profit margin was -112.85%. When comparing sales to same quarter last year, ArQule sales marked an exceptional increase and boosted a inf%. Looking back to recent quarterly results, ArQule posted 2 positive quarters in a row.
|2018-Q1||$4 M||-||$-6.53 M-157.9%||-|
|2018-Q2||$14 M||231.22%||$5.16 M37.6%||-178.93%|
|2018-Q3||$5 M||-63.67%||$-5.62 M-112.9%||-208.98%|
|2018-Q4||$3 M||-40.93%||$-8.49 M-288.6%||51.04%|
|2019-Q1||$1 M||-54.27%||$-10.27 M-763.3%||20.97%|
ArQule ownershipWhen you are planning to buy a company, it's always worth to have a look its ownership structure.
ArQule shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.74% of all shares.
Bearish positions for ARQL stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$1.0 B||$118.1 B||$157.5 M||$772.8 M||$5.9 B|
|Total shares||120.3 M||599.7 M||160.7 M||58.7 M||302.9 M|
|Float shares||93.2 M||598.3 M||134.8 M||46.4 M||293.1 M|
|- Institutional holdings (%)||81.2%||81.9%||32.5%||75.2%||77.2%|
|- Insider holdings (%)||1.7%||0.2%||0.3%||7.3%||3.4%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$7.98 - $8.53|
|Average true range||$0.55|
|50d mov avg||$9.33|
|100d mov avg||$8.74|
|200d mov avg||$6.43|
ArQule performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected Amgen, AVEO Pharmaceuticals, Cytokinetics, Exelixis, Infinity Pharmaceuticals and Eli Lilly and as the bechmarking frame for ArQule stock.
|LLYEli Lilly and||1.14%||-8.44%||11.63%|